Dr. Smith's Dashboard

Sunovion Services

Request complimentary samples of BROVANA® (arformoterol tartrate) Inhalation Solution for your patients



Need support for your patients? Ask Sunovion Answers for information about BROVANA® (arformoterol tartrate)


A dedicated team is available between 8 AM and 8 PM ET, Monday through Friday, to answer calls at 1-844-276-8262



Most Viewed

Conference Calendar

Mark your calendar:

ATS 2017

May 19 - May 24 | Washington, DC

Find more details below ▼



We can’t wait to meet you at the next conference or convention that Sunovion will be attending in 2017. See the list below to find out where we’ll be and what we’re doing in 2017!


January 1-31


February 1-28


March 1-31

MAR 16-19

AMDA 2017 Conference

The Society for Post-Acute and Long-Term Care Medicine


Phoenix Convention Center
North Building
100 North 3rd St
Phoenix, AZ 85004

Booth #301

Exhibit Details

March 16 - 17

March 16
11:00 AM - 1:45 PM
2:45 PM - 3:45 PM
4:45 PM - 7:00 PM

March 17
10:15 AM - 3:30 PM

Product Theater

Product Theater details coming soon



April 1-30


May 1-31

May 1-3

Spring Hospital Pharmacy Conference


The Westin Bonaventure
404 South Figueroa St  
Los Angeles, CA 90071

Booth #709

Exhibit Details

May 1-3

May 1
12:00 PM – 4:00 PM 

May 2
3:00 PM ‒ 5:00 PM

May 3
8:00 AM ‒ 10:00 AM

May 19-24

ATS 2017

American Thoracic Society


Walter E. Washington Convention Center
801 Mt Vernon Pl NW
Washington, DC 20001

COPD Information Booth #1537
Brovana Booth #1837

Exhibit Details

May 21‒23

May 21
10:30 AM ‒ 3:30 PM

May 22
10:30 AM ‒ 3:30 PM

May 23
10:30 AM ‒ 3:30 PM

Product Theater

Product Theater details coming soon


June 1-30


July 1-31


August 1-31

Aug 31-3

Eastern Pulmonary Conference
August 31 - September 3

Jointly Provided by the American College of Allergy, Asthma, & Immunology (ACAAI) and the Eastern Pulmonary Conference (EPC)


The Breakers Palm Beach
1 South County Rd
Palm Beach, FL 33480

Exhibit Details

September 1‒2

Product Theater

Product Theater details coming soon


September 1-30


October 1-31

OCT 4-7

AARC Congress 2017

American Association for Respiratory Care


Indianapolis location information coming soon

Booth #627

Exhibit Details

October 5-7, 2017

OCT 16-18

Fall Hospital Pharmacy Conference


Hyatt Regency O’Hare
9300 Bryn Mawr Ave
Rosemont, IL 60018

Booth details coming soon

Exhibit Details

October 16
12:00 PM ‒ 4:00 PM

October 17
1:15 PM ‒ 3:30 PM

October 18
9:30 AM ‒ 11:30 AM

OCT 28-1

CHEST 2017
October 28 - November 1

American College of Chest Physicians


Toronto location details coming soon

Booth #1804

Exhibit Details

Exhibit details coming soon


November 1-30


December 1-31

DEC 3-7

ASHP 2017 Midyear Clinical Meeting

American Society of Health-System Pharmacists


Orlando location details coming soon

Booth #1833

Exhibit Details

Exhibit details coming soon

Product Theater

Product Theater details coming soon

Important Safety Information & Indication


Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABAs, including arformoterol, the active ingredient in BROVANA.

The safety and efficacy of BROVANA in patients with asthma have not been established. BROVANA is not indicated for the treatment of asthma.

All LABAs, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication; BROVANA is also contraindicated in patients with a history of hypersensitivity to arformoterol, racemic formoterol or to any of the ingredients. 

BROVANA should not be initiated in patients with acutely deteriorating COPD or potentially life-threatening episodes of COPD, or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

BROVANA should not be used more often, at higher doses than recommended, or in conjunction with other medications containing LABAs as an overdose may result. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using BROVANA should not use another medicine containing a LABA for any reason.

Immediate hypersensitivity reactions may occur with BROVANA. If signs occur, discontinue immediately and institute alternative therapy.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Beta2-adrenergic agonists may produce significant hypokalemia in some patients.

As with other beta2-agonists, BROVANA, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because these agents may potentiate the action of adrenergic agonists on the cardiovascular system.

As with other beta2-agonists, BROVANA should be used with caution in patients treated with additional adrenergic drugs, non-potassium-sparing diuretics, and beta-blockers.

BROVANA, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

BROVANA should not be swallowed as the intended effects on the lungs will not be obtained.  BROVANA is only for oral inhalation via a standard jet nebulizer connected to an air compressor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see the full Prescribing Information including BOXED WARNING, and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution, at www.sunovionprofile.com/brovana.

BROVANA® (arformoterol tartrate) Inhalation Solution is a long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. BROVANA is for use by nebulization only.

Important limitations: BROVANA is not indicated to treat acute deteriorations of COPD and is not indicated to treat asthma.